Gateway(R) expression vector of human TOP2A.
![]() Drawn by SnapGene® software |
|
| Clone info. | Gateway(R) expression vector for human topoisomerase 2 alpha (TOP2A) driven by the CMV promoter. The TOP2A CDS contains a stop codon at its end and is not expressed as a fusion protein with the downstream Cycle 3 GFP. |
|---|---|
| Vector backbone | pcDNA-DEST47 (plasmid) |
| Size of vector backbone | 7.8 kb |
| Selectable markers | Amp^r (E. coli), Neo^r (mammalian cells). |
| Growth conditions | LB+Amp, 37℃ |
| Gene/insert name | human TOP2A cDNA |
| Depositor|Developer | Kondo, Yutaka | |
Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
| Ordering forms | Order form [Credit Card Payment MTA, for use for not-for-profit academic purpose [Word MTA, for use for for-profit purpose [Word Approval form by depositor [Word Please visit Information of Request for Distribution.[link] |
|---|---|
| Terms and conditions for distribution | Prior to requesting the BIOLOGICAL RESOURCE, the RECIPIENT must obtain approval from the DEPOSITOR using the Approval Form. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested. (Katsushima, K et al. Nat. Commun. 7: 13616, 2016); (Deguchi, S et al. Oncogene. 36 (32) : 4629 - 4640, 2017). RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. |
| Remarks | ((Additional form)) Approval Form(FormD) Please obtain written approval of the depositor. Gateway® Expression clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC. |
[open/close]| 必要書類 | 提供依頼書 提供同意書 (MTA, 非営利学術目的用)[Word 提供同意書 (MTA, 営利目的用)[Word 寄託者による提供承諾書 [Word 手続きの概要は、「提供申込みについて[link]」をご覧ください。 |
|---|---|
| MTAに書く使用条件 | 利用者は提供承諾書を用いて、事前に寄託者の承諾を得る。利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Katsushima, K et al. Nat. Commun. 7: 13616, 2016); (Deguchi, S et al. Oncogene. 36 (32) : 4629 - 4640, 2017)。利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。 |
| 備考 | 【追加提供依頼書】承諾書(FormD) 寄託者の書面による提供承諾が必要です。 Gateway®テクノロジーを用いた発現クローンです。「Gateway®テクノロジーを用いたクローンの提供と寄託のご案内」をご覧ください。 |
| Catalog # | Resource name | Shipping form | Fee |
|---|---|---|---|
| RDB15801 | pcDNA-DEST47-TOP2A | DNA solution |
Materials & Methods section:
| The pcDNA-DEST47-TOP2A was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB15801). |
Reference section:
| Deguchi, S., Katsushima, K., Hatanaka, A., Shinjo, K., Ohka, F., Wakabayashi, T., Zong, H., Natsume, A., Kondo, Y., Oncogenic effects of evolutionarily conserved noncoding RNA ECONEXIN on gliomagenesis. Oncogene 36 (32): 4629-4640 (2017). PMID 28368417. [PubMed] [Article] [RRC of NBRP] |
Further references such as user reports and related articles (go to bottom)
Original, user report and related articles
| original | Deguchi, S., Oncogenic effects of evolutionarily conserved noncoding RNA ECONEXIN on gliomagenesis. Oncogene 36 (32): 4629-4640 (2017). PMID 28368417. [PubMed] [Article] [RRC of NBRP] |
|---|
Featured content